Novocure Stock Soars, Its Lung Cancer Electric Field Treatment Slows Progression To Brain, Data Shows
Portfolio Pulse from Vandana Singh
Novocure Ltd (NASDAQ:NVCR) announced positive results from the Phase 3 METIS clinical trial for its Tumor Treating Fields (TTFields) therapy in treating brain metastases from non-small cell lung cancer. The study met its primary endpoint, showing a significant improvement in time to intracranial progression compared to supportive care alone. TTFields therapy was well-tolerated, with a median time to intracranial progression of 21.9 months versus 11.3 months for supportive care alone. Preliminary analysis of secondary endpoints showed positive trends but did not reach statistical significance. Novocure's Premarket Approval application for TTFields therapy in non-small cell lung cancer has been accepted by the FDA. Following the news, NVCR shares surged by 10.70% to $14.49.
March 27, 2024 | 2:17 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Novocure announced positive Phase 3 results for its TTFields therapy in treating brain metastases from non-small cell lung cancer, leading to a 10.70% increase in its stock price to $14.49.
The positive outcome of the Phase 3 METIS clinical trial for Novocure's TTFields therapy significantly impacts its stock price due to the potential for expanded use in treating non-small cell lung cancer. The therapy's effectiveness in delaying intracranial progression and its acceptance by the FDA for filing further bolster investor confidence in the company's growth prospects.
CONFIDENCE 90
IMPORTANCE 90
RELEVANCE 100